http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Programmed death ligand-1 expression and its prognostic role in esophageal squamous cell carcinoma
Kim, Ryul,Keam, Bhumsuk,Kwon, Dohee,Ock, Chan-Young,Kim, Miso,Kim, Tae Min,Kim, Hak Jae,Jeon, Yoon Kyung,Park, In Kyu,Kang, Chang Hyun,Kim, Dong-Wan,Kim, Young Tae,Heo, Dae Seog Baishideng Publishing Group Inc 2016 WORLD JOURNAL OF GASTROENTEROLOGY Vol.22 No.37
<P><B>AIM</B></P><P>To investigate the expression and prognostic role of programmed death ligand-1 (PD-L1) in locally advanced esophageal squamous cell carcinoma (ESCC).</P><P><B>METHODS</B></P><P>A total of 200 patients with ESCC who underwent radical esophagectomy with standard lymphadenectomy as the initial definitive treatment in Seoul National University Hospital from December 2000 to April 2013 were eligible for this analysis. Tissue microarrays were constructed by collecting tissue cores from surgical specimens, and immunostained with antibodies directed against PD-L1, p16, and c-Met. Medical records were reviewed retrospectively to assess clinical outcomes. Patients were divided into two groups by PD-L1 status, and significant differences in clinicopathologic characteristics between the two groups were assessed.</P><P><B>RESULTS</B></P><P>Tumor tissues from 67 ESCC patients (33.5%) were PD-L1-positive. Positive p16 expression was observed in 21 specimens (10.5%). The H-score for c-Met expression was ≥ 50 in 42 specimens (21.0%). Although PD-L1-positivity was not significantly correlated with any clinical characteristics including age, sex, smoking/alcoholic history, stage, or differentiation, H-scores for c-Met expression were significantly associated with PD-L1-positivity (OR = 2.34, 95%CI: 1.16-4.72, <I>P</I> = 0.017). PD-L1 expression was not significantly associated with a change in overall survival (<I>P</I> = 0.656). In contrast, the locoregional relapse rate tended to increase (<I>P</I> = 0.134), and the distant metastasis rate was significantly increased (HR = 1.72, 95%CI: 1.01-2.79, <I>P</I> = 0.028) in patients with PD-L1-positive ESCC compared to those with PD-L1-negative ESCC.</P><P><B>CONCLUSION</B></P><P>PD-L1 expression is positively correlated with c-Met expression in ESCC. PD-L1 may play a critical role in distant failure and progression of ESCC.</P>
Kim, Miso,Kim, Tae Min,Kim, Ki Hwan,Keam, Bhumsuk,Lee, Se-Hoon,Kim, Dong-Wan,Lee, Jong Seok,Jeon, Yoon Kyung,Kim, Chul Woo,Heo, Dae Seog Springer International 2015 Annals of hematology Vol.94 No.3
<P>The prognosis of patients with stage III/IV NK/T-cell lymphoma (NTCL) is extremely poor. Although L-asparaginase (L-asp) is effective for NTCL, its significance has not been clearly demonstrated. In addition, there are few studies comparing treatment outcomes in stage III/IV NTCL. This study evaluated the efficacy of L-asp-based chemotherapy and prognostic factors in stage III/IV NTCL. Seventy patients with newly diagnosed stage III/IV NTCL were enrolled between January 2000 and February 2013. Patients received ifosfamide, etoposide, methotrexate, and prednisolone (IMEP) plus L-asp (N?=?22) or combination chemotherapy without L-asp (N?=?48) as a first-line treatment. Clinical prognostic factors, treatment outcomes, and prognostic scores were compared between the groups. After a median follow-up period of 12.8 months (range, 1.1-186.6 months), median overall survival (OS) and progression-free survival (PFS) were 11.3 and 5.6 months, respectively. Treatment outcomes were superior in patients treated with IMEP plus L-asp compared to those treated with chemotherapy without L-asp (overall response rate, 90.0 vs. 34.8 %, P?<?0.001; complete remission rate, 65.0 vs. 21.7 %, P?=?0.001). The OS and PFS were significantly higher for the IMEP plus L-asp group compared with the chemotherapy without L-asp group. In a multivariate analysis, the use of chemotherapy without L-asp was an independent predictor of reduced OS (hazards ratio (HR)?=?2.18, 95 % confidence interval (CI) 1.08-4.40; P?=?0.030) and PFS (HR?=?2.29, 95 % CI 1.22-4.29; P?=?0.010). IMEP plus L-asp is active against stage III/IV NTCL, and it is an independent predictor of improved survival.</P>
2020 Korean guidelines for the management of metastatic prostate cancer
( In-Ho Kim ),( Sang Joon Shin ),( Byung Woog Kang ),( Jihoon Kang ),( Dalyong Kim ),( Miso Kim ),( Jin Young Kim ),( Chan Kyu Kim ),( Hee-Jun Kim ),( Chi Hoon Maeng ),( Kwonoh Park ),( Inkeun Park ) 대한내과학회 2021 The Korean Journal of Internal Medicine Vol.36 No.3
In 2017, Korean Society of Medical Oncology (KSMO) published the Korean management guideline of metastatic prostate cancer. This paper is the 2nd edition of the Korean management guideline of metastatic prostate cancer. We updated recent many changes of management in metastatic prostate cancer in this 2nd edition guideline. The present guideline consists of the three categories: management of metastatic hormone sensitive prostate cancer; management of metastatic castration resistant prostate cancer; and clinical consideration for treating patients with metastatic prostate cancer. In category 1 and 2, levels of evidence (LEs) have been mentioned according to the general principles of evidence-based medicine. And grades of recommendation (GR) was taken into account the quality of evidence, the balance between desirable and undesirable effects, the values and preferences, and the use of resources and GR were divided into strong recommendations (SR) and weak recommendations (WR). A total of 16 key questions are selected. And we proposed recommendations and described key evidence for each recommendation. The treatment landscape of metastatic prostate cancer is changing very rapid and many trials are ongoing. To verify the results of the future trials is necessary and should be applied to the treatment for metastatic prostate cancer patients in the clinical practice. Especially, many prostate cancer patients are old age, have multiple underlying medical comorbidities, clinicians should be aware of the significance of medical management as well as clinical efficacy of systemic treatment.
Kim, Ryul,Keam, Bhumsuk,Hahn, Seokyung,Ock, Chan-Young,Kim, Miso,Kim, Tae Min,Kim, Dong-Wan,Heo, Dae Seog Elsevier 2019 Clinical lung cancer Vol.20 No.5
<P><B>Abstract</B></P> <P><B>Background</B></P> <P>This study aimed to comprehensively review the available evidence regarding the efficacy of first-line pembrolizumab for advanced/metastatic non–small-cell lung cancer (NSCLC), and to compare pembrolizumab monotherapy versus pembrolizumab plus chemotherapy versus chemotherapy alone.</P> <P><B>Materials and Methods</B></P> <P>A search of the PubMed, EMBASE, and Cochrane Library databases was performed in July 2018, and abstracts from the American Society of Clinical Oncology meetings (2015-2018) were reviewed. Summaries of the results were pooled using a random-effect model to determine the pooled hazard ratio (HR) for progression-free survival (PFS), overall survival (OS), and their 95% confidence intervals (CIs). A network meta-analysis was used to indirectly compare pembrolizumab monotherapy with pembrolizumab plus chemotherapy.</P> <P><B>Results</B></P> <P>A total of 4 relevant phase III trials comprising 2754 patients were identified. Pembrolizumab (with or without chemotherapy) led to significant improvements in OS and PFS, irrespective of the programmed cell death ligand 1 (PD-L1) tumor proportion score (TPS). In particular, for the subgroup with PD-L1 TPS ≥ 50%, the HR of PFS was 0.49 (95% CI, 0.32-0.76; <I>P</I> = .001), and that of OS was 0.57 (95% CI, 0.45-0.73; <I>P</I> < .001). In terms of PFS, pembrolizumab plus chemotherapy was superior to pembrolizumab monotherapy with an HR of PFS 0.52 (95% CI, 0.27-0.99; <I>P</I> = .048) for the subgroup with PD-L1 TPS ≥ 50%.</P> <P><B>Conclusions</B></P> <P>For patients with NSCLC with PD-L1 TPS ≥ 50%, pembrolizumab plus chemotherapy has a better PFS than pembrolizumab monotherapy in this meta-analysis. To confirm this finding, a prospective phase III trial that directly compares the treatments is warranted.</P>
Molecular and genomic features of <i>Mycobacterium bovis</i> strain 1595 isolated from Korean cattle
Kim, Narae,Jang, Yunho,Kim, Jin Kyoung,Ryoo, Soyoon,Kwon, Ka Hee,Kim, Miso,Kang, Shin Seok,Byeon, Hyeon Seop,Lee, Hee Soo,Lim, Young-Hee,Kim, Jae-Myung The Korean Society of Veterinary Science 2017 Journal of Veterinary Science Vol.18 No.-
<P>The aim of this study was to investigate the molecular characteristics and to conduct a comparative genomic analysis of <I>Mycobacterium</I> (<I>M.</I>) <I>bovis</I> strain 1595 isolated from a native Korean cow. Molecular typing showed that <I>M. bovis</I> 1595 has spoligotype SB0140 with mycobacterial interspersed repetitive units-variable number of tandem repeats typing of 4-2-5-3-2-7-5-5-4-3-4-3-4-3, representing the most common type of <I>M. bovis</I> in Korea. The complete genome sequence of strain 1595 was determined by single-molecule real-time technology, which showed a genome of 4351712 bp in size with a 65.64% G + C content and 4358 protein-coding genes. Comparative genomic analysis with the genomes of <I>Mycobacterium tuberculosis</I> complex strains revealed that all genomes are similar in size and G + C content. Phylogenetic analysis revealed all strains were within a 0.1% average nucleotide identity value, and MUMmer analysis illustrated that all genomes showed positive collinearity with strain 1595. A sequence comparison based on BLASTP analysis showed that <I>M. bovis</I> AF2122/97 was the strain with the greatest number of completely matched proteins to <I>M. bovis</I> 1595. This genome sequence analysis will serve as a valuable reference for improving understanding of the virulence and epidemiologic traits among <I>M. bovis</I> isolates in Korea.</P>
Kim, Jin Won,Im, Seock-Ah,Kim, Miso,Cha, Yongjun,Lee, Kyung-Hun,Keam, Bhumsuk,Kim, Min A,Han, Sae-Won,Oh, Do-Youn,Kim, Tae-You,Kim, Woo Ho,Bang, Yung-Jue Potamitis Press 2012 Anticancer research Vol.32 No.4
<P>We aimed to clarify the prognostic significance of HER2 positivity in advanced gastric cancer.</P>
김문선 ( Moonsun Kim ),김민 ( Min Kim ),김미소 ( Miso Kim ),이일화 ( Ilhwa Lee ),김은수 ( Eun-soo Kim ) 사단법인 대한문신사중앙회 2020 한국문신연구학회지 Vol.1 No.1
This study will serve as an opportunity to fill the gap between "bad preconceptions by the past image of tattoo and the recognition flow as the tattoo culture of the present era becomes popular." It will be understood as a small form of social integration. With the popularization of tattoos, more and more people have used tattoos as their jobs, but controversy over medical practices, art acts and freedom of choice remains. At this point, it is necessary to find out the impact of the image of tattooing by the general public on the perception of tattoo jobs. For this study, the survey was conducted on teens to 50s from October 3, 2020 to November 12, 2020, and the results of the study were summarized using only the effective samples as the final data for the empirical analysis. The public's awareness of tattooing in each field was high, and the higher the interest in tattooing and the higher the awareness of image, the higher the professionalism of tattooing jobs and the higher the expectation for the future. As a result, despite the negative image of the past and the reality that it is considered illegal medical practice, the current tattoo was not only positive, but also the job of tattooist was highly recognized by the general public for its expertise, future expectations, and job development potential. Based on this study, we hope that research and materials that can be based on subsequent research on tattoo will be activated, which will be the basis for positive development as a new occupation group.
Heo Haejeong,Kim Jong-Hwan,Lim Hyun Jung,Kim Jeong-Hwan,Kim Miso,Koh Jaemoon,Im Joo-Young,Kim Bo-Kyung,Won Misun,Park Ji-Hwan,Shin Yang-Ji,윤미란,Cho Byoung Chul,Kim Yong Sung,Kim Seon-Young,김미랑 생화학분자생물학회 2022 Experimental and molecular medicine Vol.54 No.-
Acquired resistance to inhibitors of anaplastic lymphoma kinase (ALK) is a major clinical challenge for ALK fusion-positive non-small-cell lung cancer (NSCLC). In the absence of secondary ALK mutations, epigenetic reprogramming is one of the main mechanisms of drug resistance, as it leads to phenotype switching that occurs during the epithelial-to-mesenchymal transition (EMT). Although drug-induced epigenetic reprogramming is believed to alter the sensitivity of cancer cells to anticancer treatments, there is still much to learn about overcoming drug resistance. In this study, we used an in vitro model of ceritinib-resistant NSCLC and employed genome-wide DNA methylation analysis in combination with single-cell (sc) RNA-seq to identify cytidine deaminase (CDA), a pyrimidine salvage pathway enzyme, as a candidate drug target. CDA was hypomethylated and upregulated in ceritinib-resistant cells. CDA-overexpressing cells were rarely but definitively detected in the naïve cell population by scRNA-seq, and their abundance was increased in the acquired-resistance population. Knockdown of CDA had antiproliferative effects on resistant cells and reversed the EMT phenotype. Treatment with epigenome-related nucleosides such as 5-formyl-2′-deoxycytidine selectively ablated CDA-overexpressing resistant cells via accumulation of DNA damage. Collectively, our data suggest that targeting CDA metabolism using epigenome-related nucleosides represents a potential new therapeutic strategy for overcoming ALK inhibitor resistance in NSCLC.
김학로 ( Hak Ro Kim ),김범석 ( Bhumsuk Keam ),박영식 ( Young Sik Park ),김미소 ( Miso Kim ),김태민 ( Tae Min Kim ),김동완 ( Dong-wan Kim ),허대석 ( Dae Seog Heo ) 대한내과학회 2018 대한내과학회지 Vol.93 No.6
Nivolumab is an immune checkpoint inhibitor approved for the treatment of metastatic cancers. Here, we report the case of a 65-year-old male with recurrent renal cell carcinoma. After six cycles of nivolumab treatment, positron emission tomography/computed tomography (PET/CT) was performed to evaluate the response. PET/CT revealed diffuse ground glass opacities in both lungs. He developed a cough, sputum, chills, and a febrile sense. After bronchoscopic bronchoalveolar lavage, pneumocystis pneumonia was finally diagnosed. (Korean J Med 2018;93:571-574)